CD4 + T-cell subsets in rheumatoid arthritis

International Journal of Clinical Rheumatology

Volumn 7, Issue 1, 2012, Pages 37-53

  Ponchel, Frederique ^a   Vital, Edward ^a   Kingsbury, Sarah R ^a   El Sherbiny, Yasser M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

naive T cell; regulatory T cells; rheumatoid arthritis; Th1 Th2 Th17 subsets

Indexed keywords

ABATACEPT; CD28 ANTIGEN; CD57 ANTIGEN; METHOTREXATE;

CD4+ T LYMPHOCYTE; CELL AGING; CELL EXPANSION; CELL POLARITY; DRUG EFFECT; EARLY DIAGNOSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84856677245     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.11.69     Document Type: Review

References (227)

1. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthrit. Rheumat. 37(4), 481-494 (1994). (Pubitemid 24115934)
2. Pincus T, Breedveld FC, Emery P. Does partial control of inflammation prevent long-term joint damage? Clinical rationale for combination therapy with multiple disease-modifying antirheumatic drugs. Clin. Exp. Rheumatol. 17(6), S2-S7 (1999). (Pubitemid 29503350)
3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 376(9746), 1094-1108 (2010).
4. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv. Immunol. 56, 389-466 (1994). (Pubitemid 24242228)
5. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis -an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthrit. Rheumat. 30(11), 1205-1213 (1987). (Pubitemid 18005792)
6. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthrit. Rheumat. 33(6), 768-773 (1990). (Pubitemid 20205755)
7. Randen I, Mellbye OJ, Forre O, Natvig JB. The identification of germinal centers and follicular dendritic cell networks in rheumatoid synovial tissue Scand. J. Immunol. 41(5), 481-486 (1995).
8. Lanchbury JS, Pitzalis C. Cellular immune-mechanisms in rheumatoid arthritis and other inflammatory arthritides. Curr. Opin. Immunol. 5(6), 918-924 (1993). (Pubitemid 23347454)
9. Firestein GS, The immunopathogenesis of rheumatoid arthritis. Curr. Opin. Rheumatol. 3(3), 398-406 (1991).
10. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T-cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthrit. Rheumat. 35(7), 729-735 (1992).
11. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T cell-independent mechanisms from beginning to end. Arthrit. Rheumat. 46(2), 298-308 (2002). (Pubitemid 34136567)
12. Karouzakis E, Neidhart M, Gay RE, Gay S. Molecular and cellular basis of rheumatoid joint destruction. Immunol. Lett. 106(1), 8-13 (2006). (Pubitemid 44093056)
13. Salmon M, Gaston J. The role of lymphocytes in rheumatoid arthritis. Br. Med. Bull. 51, 332-345 (1995).
14. Londei M, Savill CM, Verhoef A et al. Persistence of collagen type-II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc. Natl Acad. Sci. USA 86(2), 636-640 (1989). (Pubitemid 19037795)
15. Goodacre JA, Pearson JP. Human cartilage proteoglycans as T cell autoantigens. Ann. Rheum. Dis. 51(9), 1094-1097 (1992).
16. Londei M, Dayan C, Feldmann M, Acuto O, Quaratino S. Human autoreactive T-cell clones show flexibility in recognizing overlapping microepitopes, but inflexibility in T-cell receptor usage, in T-cell receptor use in human autoimmune diseases. Ann. NY Acad. Sci. 756, 345-348 (1995).
17. Goronzy JJ, Bartzbazzanella P, Hu WN et al. Dominant clonotypes in the repertoire of peripheral CD4(+) T-cells in rheumatoid-arthritis. J. Clin. Invest. 94(5), 2068-2076 (1994). (Pubitemid 24348248)
18. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthrit. Rheumat. 41(12), 2108-2116 (1998). (Pubitemid 29009368)
19. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14, 397-440 (1996). (Pubitemid 26130190)
20. van der Woude D, Houwing-Duistermaat JJ, Toes RE et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthrit. Rheumat. 60(4), 916-923 (2009).
21. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthrit. Rheumat. 30(11), 1205-1213 (1987). (Pubitemid 18005792)
22. Goeb V, Dieude P, Daveau R et al. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis. Rheumatology 47(8), 1208-1212 (2008). (Pubitemid 352038228)
23. Seldin MF, Amos CI, Ward R, Gregersen PK. The genetics revolution and the assault on rheumatoid arthritis. Arthrit. Rheumat. 42(6), 1071-1079 (1999). (Pubitemid 29268942)
24. Deighton CM, Walker DJ, Griffiths ID, Roberts DF. The contribution of HLA to rheumatoid arthritis. Clin. Genet. 36(3), 178-182 (1989). (Pubitemid 19218460)
25. Gregersen PK. Susceptibility genes for rheumatoid arthritis -a rapidly expanding harvest. Bull. NYU Hosp. Joint Dis. 68(3), 179-182 (2010).
26. Padyukov L, Seielstad M, Ong RT et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheumat. Dis. 70(2), 259-265 (2011).
27. de Vries R. Genetics of rheumatoid arthritis: time for a change? Curr. Opin. Rheumatol. 23, 227-232 (2011).
28. Raychaudhuri S, Thomson BP, Remmers EF et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat. Genet. 41(12), 1313-1318 (2009).
29. Kim YO, Kim HJ, Kim SK, Chung JH, Hong SJ. Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis. Clin. Chem. Lab. Med. 48(3), 345-353 (2010).
30. Perdigones N, Vigo AG, Lamas JR et al. Evidence of epistasis between TNFRSF14 and TNFRSF6B polymorphisms in patients with rheumatoid arthritis. Arthrit. Rheumat. 62(3), 705-710 (2010).
31. Alvarez-Rodriguez L, Martinez-Taboada VM, Lopez-Hoyos M et al. Interleukin-12 gene polymorphisim in patients with giant cell arteritis, polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Clin. Exp. Rheumatol. 27(1 Suppl. 52), S14-S18 (2009).
32. Orozco G, Gonzalez-Gay MA, Paco L et al. Interleukin 12 (IL12B) and interleukin 12 receptor (IL12RB1) gene polymorphisms in rheumatoid arthritis. Hum. Immunol. 66(6), 710-715 (2005).
33. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper Type 1 and 2 lineages. Nat. Immunol. 6(11), 1123-1132 (2005). (Pubitemid 41541790)
34. Martinez A, Varade J, Marquez A et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthrit. Rheumat. 58(9), 2598-2602 (2008).
35. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 99(11), 3892-3904 (2002). (Pubitemid 35332024)
36. Moreland LW, Bucy RP, Jackson B, James T, Koopman WJ. Long term (5 years) follow-up of rheumatoid arthritis patients treated with a depleting anti-CD4 monoclonal antibody, cM-T412. Arthrit. Rheumat. 39(9), 1299-1299 (1996).
37. Isaacs JD, Greer S, Sharma S et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthrit. Rheumat. 44(9), 1998-2008 (2001). (Pubitemid 33644041)
38. Moore J, Biggs J, Milliken S et al. Immune reconstitution in patients with severe rheumatoid arthritis (RA) recieving T-cell depleted and unmanipulated autologous haemopoietic stem cell grafts (HSCT). Bone Marrow Trans. 27, S16-S17 (2001).
39. Bingham S, Veale D, Fearon U et al. High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthrit. Rheumat. 46(3), 837-839 (2002). (Pubitemid 34214267)
40. Bingham S, Veale D, Fearon U et al. Long-term follow-up of highly selected autologous stem cell transplantation in severe rheumatoid arthritis with studies of peripheral blood reconstitution and macroscopic and histological arthroscopic appearances. Arthrit. Rheumat. 43(9), Abstract S290 (2000).
41. Goronzy JJ, Fujii H, Weyand CM. Telomeres, immune aging and autoimmunity. Exp. Gerontol. 41(3), 246-251 (2006).
42. Schonland SO, Lopez C, Widmann T et al. Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proc. Natl Acad. Sci. USA 100(23), 13471-13476 (2003). (Pubitemid 37444766)
43. Koetz K, Spickschen K, Goronzy JJ, Weyand CM. Premature aging in the immune system of patients with rheumatoid arthritis. Arthrit. Rheumat. 41(9) Abstract S1994 (1998).
44. Desai A, Grolleau-Julius A, Yung R. Leukocyte function in the aging immune system. J. Leuk. Biol. 87(6), 1001-1009 (2010).
45. Douek DC, McFarland RD, Keiser PH et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396(6712), 690-695 (1998). (Pubitemid 29003949)
46. Ponchel F, Morgan A, Bingham S et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 100, 4550-4556 (2002). (Pubitemid 35429697)
47. Ponchel F, Verburg R, Bingham S et al. IL-7 deficiency and therapy-induced lymphopenia in rheumatoid arthritis. Arthrit. Res. Ther. 7, 80-92 (2005).
48. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 95(24), 14447-14452 (1998). (Pubitemid 28549387)
49. Hingorani R, Monteiro J, Furie R et al. Oligoclonality of V ? 3 TCR chains in the CD8(+) T cell population of rheumatoid arthritis patients. J. Immunol. 156(2), 852-858 (1996).
50. Hall FC, Thomson K, Procter J, McMichael AJ, Wordsworth BP. TCR spectratyping in RA: evidence of clonal expansions in peripheral blood lymphocytes. Ann. Rheumat. Dis. 57(5), 319-322 (1998). (Pubitemid 28351102)
51. Walser-Kuntz DR, Weyand CM, Weaver AJ, Ofallon WM, Goronzy JJ. Mechanisms underlying the formation of the T-cell receptor repertoire in rheumatoid arthritis. Immunity 2(6), 597-605 (1995).
52. Walser-Kuntz DR, Weyand CM, Goronzy JJ. Influence of antigenic experience on BJ gene segment usage in human CD4(+) T cells. Int. Immunol. 9(12), 1785-1792 (1997). (Pubitemid 28005816)
53. Pincus T, Callahan LF. The side-effects of rheumatoid arthritis -joint destruction, disability and early mortality. Br. J. Rheumatol. 32, 28-37 (1993). (Pubitemid 23089038)
54. Allen ME, Young SP, Michell RH, Bacon PA. Altered T-lymphocyte signaling in rheumatoid arthritis. Eur. J. Immunol. 25(6), 1547-1554 (1995).
55. Mirza NM, Relias V, Yunis EJ, Pachas WN, Dasgupta JD. Defective signal transduction via T-cell receptor-CD3 structure in T cells from rheumatoid arthritis patients. Hum. Immunol. 36(2), 91-98 (1993). (Pubitemid 23097302)
56. Maurice MM, Lankester AC, Bezemer AC et al. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J. Immunol. 159(6), 2973-2978 (1997). (Pubitemid 127681320)
57. Breedveld FC, Gringhuis SI, Maurice MM, Verweij CL. Redox balance alterations and hyporesponsiveness of synovial T cells in rheumatoid arthritis. Arthrit. Res. Ther. 1(Suppl. 1), Abstract S4 (2000).
58. Maurice N, Makumura H, van der Voort E. Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis. J. Immunol. 158, 1458-1465 (1997). (Pubitemid 127469974)
59. Cope AP, Liblau RS, Yang XD et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 185(9), 1573-1584 (1997). (Pubitemid 27203254)
60. Ali M, Ponchel F, Wilson KE et al. Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. J. Clin. Invest. 107(4), 519-528 (2001). (Pubitemid 32167998)
61. Remans PH, Gringhuis SI, van Laar JM et al. Rap1 signaling is required for suppression of Ras-generated reactive oxygen species and protection against oxidative stress in T lymphocytes. J. Immunol. 173(2), 920-931 (2004). (Pubitemid 38924265)
62. Remans PH, Wijbrandts CA, Sanders ME et al. CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells. Arthrit. Rheumat. 54(10), 3135-3143 (2006). (Pubitemid 44622084)
63. Abreu JRF, Krausz S, Dontje W et al. Sustained T cell Rap1 signaling is protective in the collagen-induced arthritis model of rheumatoid arthritis. Arthrit. Rheumat. 62(11), 3289-3299 (2010).
64. Atsumi T, Ishihara K, Kamimura D et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196(7), 979-990 (2002).
65. Lehmann U, Schmitz J, Weissenbach M et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J. Biol. Chem. 278(1), 661-671 (2003). (Pubitemid 36043620)
66. Sawa S, Kamimura D, Jin GH et al. Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4(+) T cells. J. Exp. Med. 203(6), 1459-1470 (2006). (Pubitemid 43877608)
67. Sakaguchi N, Takahashi T, Hata H et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426(6965), 454-460 (2003). (Pubitemid 37490133)
68. Unutmaz D, Baldoni F, Abrignani S. Human naive T-cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory T-cells. Int. Immunol. 7, 1417-1424 (1995).
69. Hakim FT, Gress RE. Immunosenescence: deficits in adaptive immunity in the elderly. Tis. Antigens 70(3), 179-189 (2007). (Pubitemid 47106657)
70. Saule P, Trauet J, Dutriez V et al. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech. Ageing Develop. 127(3), 274-281 (2006). (Pubitemid 43214500)
71. Burgoyne C, Field S, Brown AK et al. Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse. Ann. Rheumat. Dis. 67, 750-757 (2008). (Pubitemid 351829373)
72. Unumtaz D, Pileri P, Abrignani S. Antigen-independent activation of naive and memory resting T-cells by a cytokine combination. J. Exp. Med. 180, 1159-1164 (1994). (Pubitemid 24256630)
73. Hintzen RQ, de Jong R, Lens SM et al. Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 151(5), 2426-2435 (1993). (Pubitemid 23264495)
74. Schiott A, Lindstedt M, Johansson-Lindbom B, Roggen E, Borrebaeck CA. CD27-CD4+ memory T cells define a differentiated memory population at both the functional and transcriptional levels. Immunology 113(3), 363-370 (2004). (Pubitemid 39472153)
75. Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 6(9), 895-901 (2005). (Pubitemid 43090444)
76. Campbell J, Murphy K, Kunkel E et al. CCR7 expression and memory T cell diversity in humans. J. Immunol. 166, 877-884 (2001). (Pubitemid 32060241)
77. Vallejo AN, Bryl E, Klarskov K et al. Molecular basis for the loss of CD28 expression in senescent T cells. J. Biol. Chem. 277(49), 46940-46949 (2002). (Pubitemid 36159198)
78. Thewissen M, Somers V, Hellings N et al. CD4(+)CD28(null) T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J. Immunol. 179, 6514-6523 (2007).
79. Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4(+)CD28(null) T cells are associated with defects in apoptotic pathways. J. Immunol. 165(11), 6301-6307 (2000).
80. Fasth AE, Cao D, van Vollenhoven R, Trollmo C, Malmstrom V. CD28(null) CD4(+) T cells -characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand. J. Immunol. 60(1-2), 199-208 (2004). (Pubitemid 38943068)
81. Schmidt D, Goronzy JJ, Weyand CM. CD4(+) CD7(-) CD28(-) T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J. Clin. Invest. 97(9), 2027-2037 (1996). (Pubitemid 26143956)
82. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthrit. Rheumat. 40(6), 1106-1114 (1997). (Pubitemid 27242298)
83. Hooper M, Kallas EG, Coffin D et al. Cytomegalovirus seropositivity is associated with the expansion of CD4+CD28-and CD8+CD28-T cells in rheumatoid arthritis. J. Rheumatol. 26(7), 1452-1457 (1999). (Pubitemid 29317864)
84. Wagner U, Pierer M, Kaltenhauser S et al. Clonally expanded CD4(+)CD28(null) T cells in rheumatoid arthritis use distinct combinations of T cell receptor BV and BJ elements. Eur. J. Immunol. 33(1), 79-84 (2003). (Pubitemid 36157645)
85. Namekawa T, Snyder MR, Yen JH et al. Killer cell activating receptors function as costimulatory molecules on CD4(+) CD28(null) T cells clonally expanded in rheumatoid arthritis. J. Immunol. 165(2), 1138-1145 (2000). (Pubitemid 30484786)
86. Warrington KJ, Takemura S, Goronzy JJ, Weyand CM. CD4+,CD28-T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthrit. Rheumat. 44(1), 13-20 (2001). (Pubitemid 32113113)
87. van Bergen J, Thompson A, van der Slik A et al. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J. Immunol. 173(11), 6719-6726 (2004). (Pubitemid 39541057)
88. Snyder MR, Muegge LO, Offord C et al. Formation of the killer Ig-like receptor repertoire on CD4(+)CD28(null) T cells. J. Immunol. 168(8), 3839-3846 (2002). (Pubitemid 34298385)
89. Gerli R, Schillaci G, Giordano A et al. CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109(22), 2744-2748 (2004). (Pubitemid 38737922)
90. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood 101(9), 3543-3549 (2003). (Pubitemid 36857940)
91. Dangeac AD, Monier S, Jorgensen C et al. Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. Arthrit. Rheumat. 36(5), 608-612 (1993). (Pubitemid 23149907)
92. Dangeac AD, Monier S, Pilling D et al. CD57+ T lymphocytes are derived from CD57-precursors by differentiation occurring in late immune responses. Eur. J. Immunol. 24(7), 1503-1511 (1994). (Pubitemid 24203752)
93. Morley JK, Batliwalla FM, Hingorani R, Gregersen PK. Oligoclonal CD8+ T cells are preferentially expanded in the CD57+ subset. J. Immunol. 154(11), 6182-6190 (1995).
94. Arai K, Yamamura S, Seki S et al. Increase of CD57(+) T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role. Clin. Exp. Immunol. 111(2), 345-352 (1998). (Pubitemid 28088316)
95. Imberti L, Sottini A, Signorini S, Gorla R, Primi D. Oligoclonal CD4(+)CD57(+) T-cell expansions contribute to the imbalanced T-cell receptor repertoire of rheumatoid arthritis patients. Blood 89(8), 2822-2832 (1997). (Pubitemid 27172568)
96. Maeda T, Yamada H, Nagamine R et al. Involvement of CD4+CD57+T cells in the disease activity of rheumatoid arthritis. Arthrit. Rheumat. 46(2), 379-384 (2002). (Pubitemid 34136575)
97. Wang ECY, Lawson TM, Vedhara K et al. CD8(high)+ (CD57+) T cells in patients with rheumatoid arthritis. Arthrit. Rheumat. 40(2), 237-248 (1997). (Pubitemid 27114087)
98. Shinomiya N, Koike Y, Koyama H et al. Analysis of the susceptibility of CD57(+) T cells to CD3-mediated apoptosis. Clin. Exp. Immunol. 139(2), 268-278 (2005). (Pubitemid 40222844)
99. Asnagli H, Murphy KM. Stability and commitment in T helper cell development. Curr. Opin. Immunol. 13(2), 242-247 (2001). (Pubitemid 32176045)
100. Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur. J. Immunol. 40(12), 3312-3316 (2010).
101. de Jong E, Suddason T, Lord GM. Translational mini-review series on Th17 cells: development of mouse and human T helper 17 cells. Clin. Exp. Immunol. 159(2), 148-158 (2010).
102. Lohr J, Knoechel B, Caretto D, Abbas AK. Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect. 11(5), 589-593 (2009).
103. Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 41(2), 87-102 (2008).
104. Becher B, Blain M, Giacomini PS, Antel JP. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J. Immunol. 162(2), 684-688 (1999). (Pubitemid 29035387)
105. Aerts NE, De Knop KJ, Leysen J et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology 49(12), 2264-2272 (2010).
106. Aarvak T, Chabaud M, Kallberg E, Miossec P, Natvig JB. Change in the Th1/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium. Scand. J. Immunol. 50(1), 1-9 (1999). (Pubitemid 29298019)
107. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthrit. Res. Ther. 7, S4-S14 (2005). (Pubitemid 40936615)
108. Kawashima M, Miossec P. Defective Th1 immune response in the peripheral blood from patients with active Rheumatoid arthritis (RA): possible contribution to tuberculosis during anti-TNF treatment. Arthrit. Rheumat. 48(9), 24 (2003).
109. Kawashima M, Miossec P. mRNA quantification of T-bet, GATA-3, IFN, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J. Clin. Immunol. 25(3), 209-214 (2005). (Pubitemid 40884046)
110. de Saint-Vis B, Fugier-Vivier I, Massacrier C et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. 160(4), 1666-1676 (1998). (Pubitemid 28106451)
111. Vasir B, Avigan D, Wu Z et al. Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism. J. Immunol. 174(4), 2376-2386 (2005). (Pubitemid 40223987)
112. Lawson C, Griffiths B, Ponchel F et al. Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis -results of a pilot safety study. Rheumatology 44(S1), Abstract i24 (2005).
113. Churchman S, Ponchel F. IL-7 in rheumatoid arthritis. Rheumatology 6, 753-759 (2008).
114. Ponchel F, Brown AK, Field SL et al. T-bet expression in RA patients with early, DMARDs naive disease is low and correlates with low levels of IL-7 and T-cell dysfunctions. Arthrit. Rheumat. Abstract S525(2004).
115. van Roon JAG, Glaudemans CA, Bijlsma JWJ, Lafeber F. Differentiation of naive CD4(+) T cells towards T helper 2 cells is not impaired in rheumatoid arthritis patients. Arthrit. Res. Ther. 5(5), R269-R276 (2003).
116. Malfait AM, Butler DM, Presky DH et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111(2), 377-383 (1998). (Pubitemid 28088321)
117. Butler DM, Malfait AM, Maini RN, Brennan FM, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. 29(7), 2205-2212 (1999). (Pubitemid 29313095)
118. Horsfall AC, Butler DM, Marinova L et al. Suppression of collagen-induced arthritis by continuous administration of IL-4. J. Immunol. 159(11), 5687-5696 (1997). (Pubitemid 127470100)
119. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6(11), 1133-1141 (2005). (Pubitemid 41541791)
120. Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126(6), 1121-1133 (2006). (Pubitemid 44380299)
121. Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol. Rev. 226, 160-171 (2008).
122. Evans HG, Gullick NJ, Kelly S et al. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc. Natl Acad. Sci. USA 106(15), 6232-6237 (2009).
123. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 T helper cells origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol. 5(6), 325-331 (2009).
124. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. The phenotype of human T(h)17 cells and their precursors, the cytokines that mediate their differentiation and the role of T(h)17 cells in inflammation. Int. Immunol. 20(11), 1361-1368 (2008).
125. He R, Shepard LW, Chen J, Pan ZK, Ye RD. Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J. Immunol. 177(6), 4072-4079 (2006). (Pubitemid 44359941)
126. Patel DN, King CA, Bailey SR et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-B and C/EBP activation. J. Biol. Chem. 282(37), 27229-27238 (2007). (Pubitemid 47501976)
127. Chabaud M, Garnero P, Dayer JM et al. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12(7), 1092-1099 (2000). (Pubitemid 30479493)
128. Jovanovic DV, Martel-Pelletier J, Di Battista JA et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthrit. Rheumat. 43(5), 1134-1144 (2000). (Pubitemid 30368194)
129. Rifas L, Arackal S. T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism. Arthrit. Rheumat. 48(4), 993-1001 (2003). (Pubitemid 36418241)
130. Oukka M. Th17 cells in immunity and autoimmunity. Ann. Rheumat. Dis. 67(Suppl. 3), iii26-iii29 (2008).
131. Nakae S, Saijo S, Horai R et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl Acad. Sci. USA 100(10), 5986-5990 (2003). (Pubitemid 36576918)
132. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171(11), 6173-6177 (2003). (Pubitemid 37467240)
133. Hirota K, Hashimoto M, Yoshitomi H et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J. Exp. Med. 204(1), 41-47 (2007). (Pubitemid 46148754)
134. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41(2), 84-91 (2008).
135. Lubberts E, Koenders MI, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthrit. Rheumat. 50(2), 650-659 (2004). (Pubitemid 38198849)
136. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 43(3), 402-407 (2008).
137. Church LD, Filer AD, Hidalgo E et al. Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-?co-expression, but little interleukin-22 and interleukin-23R expression. Arthrit. Res. Ther. 12(5), R184 (2010).
138. Kattah MG, Wong MT, Yocum MD, Utz PJ. Cytokines secreted in response to toll-like receptor ligand stimulation modulate differentiation of human Th17 cells. Arthrit. Rheumat. 58(6), 1619-1629 (2008). (Pubitemid 351847515)
139. Colin EM, Asmawidjaja PS, van Hamburg JP et al. 1,25-dihydroxyvitamin D-3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthrit. Rheumat. 62(1), 132-142 (2011).
140. Takeyama K, Kato S. The vitamin D3 1?-hydroxylase gene and its regulation by active vitamin D3. Biosci. Biotechnol. Biochem. 75(2), 208-213 (2011).
141. Hueber AJ, Asquith DL, Miller AM et al. Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J. Immunol. 184(7), 3336-3340 (2010).
142. Adamopoulos IE, Bowman EP. Immune regulation of bone loss by Th17 cells. Arthrit. Res. Ther. 10(5), 225 (2008).
143. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203(12), 2673-2682 (2006). (Pubitemid 44833343)
144. Kato H, Fox DA. Are Th17 cells an appropriate new target in the treatment of rheumatoid arthritis? Clin. Trans. Sci. 3(6), 319-326 (2010).
145. Annunziato F, Cosmi L, Manetti R et al. Reversal of human allergen-specific CRTH2+ T(H)2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide. J. Allergy Clin. Immunol. 108(5), 815-821 (2001). (Pubitemid 33096216)
146. Hegazy AN, Peine M, Helmstetter C et al. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity 32(1), 116-128 (2010).
147. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204(8), 1849-1861 (2007). (Pubitemid 47240944)
148. Cosmi L, Maggi L, Santarlasci V et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J. Allergy Clin. Immunol. 125(1), 222-230.e1-e4 (2010).
149. Dardalhon V, Awasthi A, Kwon H et al. IL-4 inhibits TGF-? -induced Foxp3+ T cells and, together with TGF-, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 9(12), 1347-1355 (2008).
150. Veldhoen M, Uyttenhove C, van Snick J et al. Transforming growth factor-? "reprograms" the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9(12), 1341-1346 (2008).
151. Nowak EC, Weaver CT, Turner H et al. IL-9 as a mediator of Th17-driven inflammatory disease. J. Exp. Med. 206(8), 1653-1660 (2009).
152. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10(8), 864-871 (2009).
153. Elyaman W, Bradshaw EM, Uyttenhove C et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl Acad. Sci. USA 106(31), 12885-12890 (2009).
154. Chang HC, Sehra S, Goswami R et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11(6), 527-534 (2010).
155. Jager A, Kuchroo VK. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand. J. Immunol. 72(3), 173-184 (2010).
156. Eyerich S, Eyerich K, Pennino D et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 119(12), 3573-3585 (2009).
157. Zhang L, Li JM, Liu XG et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31(4), 606-614 (2011).
158. Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol. Cell Biochem. 353(1-2), 41-46 (2011).
159. Breitfeld D, Ohl L, Kremmer E et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192(11), 1545-1552 (2000).
160. Schaerli P, Willimann K, Lang AB et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192(11), 1553-1562 (2000).
161. Nurieva RI, Chung Y, Martinez GJ et al. Bcl6 mediates the development of T follicular helper cells. Science 325(5943), 1001-1005 (2009).
162. Johnston RJ, Poholek AC, DiToro D et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325(5943), 1006-1010 (2009).
163. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol. Rev. 204, 55-73 (2005). (Pubitemid 40460493)
164. Meier D, Bornmann C, Chappaz S et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue- inducer cells. Immunity 26(5), 643-654 (2007). (Pubitemid 46756355)
165. Timmer TC, Baltus B, Vondenhoff M et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthrit. Rheumat. 56(8), 2492-2502 (2007). (Pubitemid 47237268)
166. Sakaguchi S, Sakaguchi N. Organ-specific autoimmune-disease induced in mice by elimination of T-cell subsets: neonatal administration of cyclosporine-a causes autoimmune-disease. J. Immunol. 142(2), 471-480 (1989). (Pubitemid 19039964)
167. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunological self-tolerance maintained by activated T-cells expressing Il-2 receptor ?-Chains (Cd25) -breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151-1164 (1995).
168. Kayashima K, Koga T, Onoue K. Role of T lymphocytes in adjuvant arthritis. I. Evidence for the regulatory function of thymus-derived cells in the induction of the disease. J. Immunol. 117(5), 1878-1882 (1976).
169. Strelkauskas AJ, Callery RT, McDowell J, Borel Y, Schlossman SF. Direct evidence for loss of human suppressor cells during active autoimmune disease. Proc. Natl Acad. Sci. USA 75(10), 5150-5154 (1978). (Pubitemid 9046499)
170. Strelkauskas AJ, Schauf V, Wilson BS, Chess L, Schlossman SF. Isolation and characterization of naturally occurring subclasses of human peripheral blood T cells with regulatory functions. J. Immunol. 120(4), 1278-1282 (1978). (Pubitemid 8343832)
171. Damle NK, Mohagheghpour N, Kansas GS, Fishwild DM, Engleman EG. Immunoregulatory T cell circuits in man. Identification of a distinct T cell subpopulation of the helper/inducer lineage that amplifies the development of alloantigen-specific suppressor T cells. J. Immunol. 134(1), 235-243 (1985). (Pubitemid 15191503)
172. Cosulich ME, Risso A, Canonica GW, Bargellesi A. Functional characterization of a regulatory human T-cell subpopulation increasing during autologous MLR. Immunology 57(2), 265-273 (1986). (Pubitemid 16135741)
173. Dobloug JH, Forre O, Chattopadhyay C, Natvig JB. Concanavalin A induces suppressor cell activity in both T ? and T non-? cells: most of the suppressor cells do not carry HLA-DR antigens. Scand. J. Immunol. 15(1), 87-95 (1982). (Pubitemid 12150679)
174. Smolen JS, Lanzer G, Scherak O et al. Suppressor cell activity in rheumatoid arthritis correlation with serologic features and therapy. Clin. Res. 29(3), Abstract 676A (1981).
175. Dobloug JH, Chattopadhyay C, Forre O, Hoyeraal HM, Natvig JB. Con A-induced suppressor cell activity and T-lymphocyte subpopulations in peripheral blood lymphocytes of patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Scand. J. Immunol. 13(4), 367-373 (1981). (Pubitemid 11147255)
176. Panush RS. Nonspecific suppressor function in rheumatoid arthritis. J. Clin. Lab. Immunol. 9(1), 59-64 (1982). (Pubitemid 12004321)
177. Patel V, Panayi GS, Shepherd P et al. Lymphocyte studies in rheumatoid arthritis. V. Suppressor cell function in peripheral blood. Scand. J. Rheumatol. 11(3), 133-137 (1982). (Pubitemid 12030865)
178. Alpert SD, Koide J, Takada S, Engleman EG. T cell regulatory disturbances in the rheumatic diseases. Rheumat. Dis. Clin. N. Am. 13(3), 431-445 (1987).
179. Myers LK, Stuart JM, Kang AH. A CD4 cell is capable of transferring suppression of collagen-induced arthritis. J. Immunol. 143(12), 3976-3980 (1989). (Pubitemid 20012582)
180. Kanof ME, Strober W, James SP. Induction of CD4 suppressor T cells with anti-Leu-8 antibody. J. Immunol. 139(1), 49-54 (1987). (Pubitemid 17091759)
181. Murakawa Y, Strober W, James SP. Monoclonal antibody against the human peripheral lymph node homing receptor homologue (Leu 8) inhibits B cell differentiation but not B cell proliferation. J. Immunol. 146(1), 40-46 (1991).
182. Goto M, Miyamoto T, Nishioka K, Okumura K. Selective loss of suppressor T cells in rheumatoid arthritis patients: analysis of peripheral blood lymphocytes by 2-dimensional flow cytometry. J. Rheumatol. 13(5), 853-857 (1986). (Pubitemid 17203913)
183. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4(+)CD25(+) regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199(7), 971-979 (2004). (Pubitemid 38481088)
184. Cao D, Malmström V, Baecher-Allan C et al. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur. J. Immunol. 33, 215-223 (2003). (Pubitemid 36157659)
185. de Kleer IM, Wedderburn LR, Taams LS et al. CD4(+)CD25(bright) regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172(10), 6435-6443 (2004). (Pubitemid 38621253)
186. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196(3), 389-399 (2002). (Pubitemid 34875667)
187. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-herapy. J. Exp. Med. 200(3), 277-285 (2004). (Pubitemid 39031247)
188. Kriegel MA, Lohmann T, Gabler C et al. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type 2. J. Exp. Med. 199(9), 1285-1291 (2004). (Pubitemid 38620265)
189. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3(3), 199-210 (2003). (Pubitemid 37323205)
190. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25(+) T cells. Immunology 107(1), 5-9 (2002).
191. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4(+)CD25(+) regulatory T cells control Leishmania major persistence and immunity. Nature 420(6915), 502-507 (2002). (Pubitemid 35477041)
192. Boyer O, Saadoun D, Abriol J et al. CD4(+) CD25(+) regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 103(9), 3428-3430 (2004). (Pubitemid 38525674)
193. Karim M, Bushell AR, Wood KJ. Regulatory T cells in transplantation. Curr. Opin. Immunol. 14(5), 584-591 (2002). (Pubitemid 35232145)
194. Mottonen M, Heikkinen J, Mustonen L et al. CD4(+) CD25(+) T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Immunol. 140(2), 360-367 (2005). (Pubitemid 40559165)
195. van Amelsfort JMR, Jacobs KMG, Bijlsma JWJ, Lafeber F, Taams LS. CD4+CD25+ regulatory T cells in rheumatoid arthritis -differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthrit. Rheumat. 50(9), 2775-2785 (2004). (Pubitemid 39209514)
196. Abdulahad WH, Boots AMH, Kallenberg CGM. FoxP3(+) CD4(+) T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells. Rheumatology 50(4), 646-656 (2011).
197. Lawson C, Brown A, Greenstein A et al. Rheumatoid arthritis is associated with a deficit in CD4+CD25high regulatory T-cell in the peripheral blood. Rheumatology 45, 1210-1217 (2006). (Pubitemid 44548851)
198. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-herapy. J. Exp. Med. 200(3), 277-285 (2004). (Pubitemid 39031247)
199. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 105(49), 19396-19401 (2008).
200. Valencia X, Stephens G, Goldbach-Mansky R et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108(1), 253-261 (2006). (Pubitemid 43990636)
201. Ruprecht CR, Gattorno M, Ferlito F et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. 201(11), 1793-1803 (2005). (Pubitemid 41002898)
202. Liu W, Putnam AL, Xu-Yu Z et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203(7), 1701-1711 (2006). (Pubitemid 44036276)
203. Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203(7), 1693-1700 (2006). (Pubitemid 44036275)
204. Saleem B, Keen H, Goeb V et al. RA patients in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann. Rheum. Dis. 69(9), 1636-1642 (2010).
205. Hong Q, Song XY, Huang JY, Guo Y. CD4(+) CD25(+)Foxp3(+) regulatory T cell content in peripheral blood and synovial fluid of patients with rheumatoid arthritis and osteoarthritis. Chin. J. Biol. 24(2), 169-172 (2011).
206. Zaiss MM, Frey B, Hess A et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J. Immunol. 184(12), 7238-7246 (2010).
207. Yuan FL, Li X, Lu WG et al. Regulatory T cells as a potent target for controlling bone loss. Biochem. Biophys. Res. Commun. 402(2), 173-176 (2010).
208. Koenen HJ, Smeets RL, Vink PM et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112(6), 2340-2352 (2008).
209. Cao DJ, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD25(bright) CD4(+) regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthrit. Res. Ther. 6(4), R335-R346 (2004).
210. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF. J. Immunol. 178(11), 6725-6729 (2007). (Pubitemid 46847395)
211. Hill JA, Hall JA, Sun CM et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 29(5), 758-770 (2008).
212. Nolting J, Daniel C, Reuter S et al. Retinoic acid can enhance conversion of naive into regulatory T cells independently of secreted cytokines. J. Exp. Med. 206(10), 2131-2139 (2009).
213. Zhou XH, Kong N, Wang J et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J. Immunol. 185(5), 2675-2679 (2010).
214. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br. J. Haematol. 99(1), 9-22 (1997). (Pubitemid 27461321)
215. Isaacs JD, Watts RA, Hazleman BL et al. Humanized monoclonal-antibody therapy for rheumatoid-arthritis. Lancet 340(8822), 748-752 (1992).
216. Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ. Emergence of oligoclonal T-cell populations following therapeutic T-cell depletion in rheumatoid-arthritis. Arthrit. Rheumat. 38(9), 1242-1251 (1995).
217. Moreland LW, Bucy RP, Knowles RW et al. Treating rheumatoid arthritis with a non-depleting anti-Cd4 monoclonal antibody (Mab). Arthrit. Rheumat. 38(9), 199-199 (1995).
218. Mackie S, Vital E, Ponchel F, Emery P. Co-stimulatory blockade as therapy for rheumatoid arthritis. Curr. Rheumatol. Reports 7, 400-406 (2005).
219. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907-1915 (2003). (Pubitemid 37409707)
220. Seidel M, Keck R, Vetter H. ICAM-1/LFA-1 expression in acute osteodestructive joint lesions in collagen-induced arthritis in rats. J. Histochem. Cytochem. 45, 1247-1254 (1997).
221. Bryl E, Vallejo AN, Matteson EL et al. Modulation of CD28 expression with anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthrit. Rheumat. 52(10), 2996-3003 (2005). (Pubitemid 41447078)
222. Ponchel F, Parmar R, Nam J et al. Naïve T-cells predict MTX induced remission in early arthritis. Presented at: 31st European Workshop for Rheumatology Research. Amsterdam, The Netherlands, 3-6 March 2011.
223. Kawashima M, Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann. Rheumat. Dis. 64(3), 415-418 (2005). (Pubitemid 40283052)
224. Vital EM, El Sherbiny Y, Parmar R, Emery P, Ponchel F. Regulatory and naive t cell numbers increase after rituximab therapy in rheumatoid arthritis. Ann. Rheum. Dis. 70(3)Abstract S523 (2011).
225. Tang TT, Song Y, Ding YJ et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J. Lipid Res. 52(5), 1023-1032 (2011).
226. Allan SE, Crome SQ, Crellin NK et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19(4), 345-354 (2007). (Pubitemid 46523383)
227. Wright GP, Ehrenstein MR, Stauss HJ. Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Exp. Rev. Clin. Immunol. 7(2), 213-225 (2011).